Vaccine Immunogenicity, Efficacy, and Safety

Immunogenicity is the immune response a vaccine measurably induces; efficacy is the reduction in disease it produces under trial conditions; effectiveness is the protection it delivers in real-world use; and safety is the profile of its adverse effects. A central problem of vaccinology is linking the measurable immune response to actual protection through a correlate of protection.

Definition

Immunogenicity is the magnitude and quality of the immune response a vaccine elicits; efficacy is the proportional reduction in disease incidence among vaccinated versus unvaccinated participants in a controlled trial; effectiveness is the analogous benefit observed in routine use; and a correlate of protection is an immune marker statistically associated with protection.

Scope

This topic covers how vaccine-induced immunity is measured, how protection is quantified in trials and in the field, and how a correlate of protection bridges the two. It also frames the assessment of vaccine safety. It is an educational account of these concepts and their evidence base, not guidance on whether an individual should be vaccinated.

Core questions

• How is vaccine-induced immunity measured?
• What is the difference between efficacy and effectiveness?
• What makes an immune marker a valid correlate of protection?
• How are vaccine safety and rare adverse events assessed?
• Why can a strong immune response still fail to predict protection?

Key concepts

• Immunogenicity
• Vaccine efficacy
• Vaccine effectiveness
• Correlate of protection
• Neutralizing antibody titre
• Cell-mediated immunity
• Reactogenicity and adverse events
• Durability and waning of immunity

Mechanisms

After vaccination, immunogenicity is gauged by assays such as neutralizing-antibody titres and measures of T-cell response; these reflect, but do not equal, protection. Efficacy is established by comparing disease incidence between vaccinated and placebo groups in a randomized trial, as in the BNT162b2 and mRNA-1273 studies (Polack et al., 2020; Baden et al., 2021), whereas effectiveness is estimated observationally once a vaccine is in use. The conceptual link is the correlate of protection — an immune measurement that predicts who is protected — formalized by Plotkin (2010). For SARS-CoV-2, Khoury et al. (2021) showed that neutralizing-antibody levels were highly predictive of protection from symptomatic infection, illustrating a quantitative correlate. Safety is assessed through reactogenicity monitoring in trials and post-licensure surveillance for rarer events.

Clinical relevance

These concepts explain how the benefit and risk of a vaccine are established and communicated, and they underpin the appraisal of any vaccine's evidence. The entry describes how efficacy, effectiveness, and safety are measured and interpreted; it does not advise on individual vaccination decisions, which depend on clinical judgement and current public-health guidance.

History

The idea that a measurable immune marker could stand in for clinical protection matured over decades of vaccinology and was synthesized by Plotkin (2010), whose framework of correlates of protection became a reference point. The COVID-19 vaccine trials and subsequent meta-analyses (Polack et al., 2020; Khoury et al., 2021) provided large modern datasets connecting antibody levels to measured protection.

Debates

Is a single antibody threshold a sufficient correlate of protection?

Neutralizing-antibody titres predict protection well for several viruses, but cell-mediated immunity and waning over time complicate reliance on any single threshold, so the field treats correlates as useful but partial surrogates.

Key figures

• Stanley Plotkin
• Andrew Pollard

Seminal works

• plotkin-2010
• khoury-2021

Frequently asked questions

What is the difference between vaccine efficacy and effectiveness?

Efficacy is the protection measured under the controlled conditions of a randomized trial, while effectiveness is the protection observed when the vaccine is used in the general population, where conditions are less controlled.

What is a correlate of protection?

It is an immune measurement, often a neutralizing-antibody level, that is statistically associated with being protected, allowing protection to be predicted without waiting to observe disease in every individual.